<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687999</url>
  </required_header>
  <id_info>
    <org_study_id>KMUH-IRB-940055</org_study_id>
    <nct_id>NCT00687999</nct_id>
  </id_info>
  <brief_title>NIDDM and IR in Combination Therapy for CHC</brief_title>
  <official_title>Non-insulin-dependent Diabetes Mellitus and Insulin Resistance in Chronic Hepatitis C Patients Treated With Combination Therapy With Pegylated Interferon and Ribavirin in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The influence of insulin sensitivity and glucose tolerance on the effects of antiviral
      therapy for HCV remains unclear. The aim of the present study was (1) To elucidate the
      clinical and virological factors associated with sustained viral response in patients with
      combination therapy with PEG-IFN and ribavirin. (2) To clarify the influence of diabetes
      mellitus (DM), impaired glucose tolerance test (IGT) and insulin resistance (IR) on the HCV
      response to combination therapy with PEG-IFN and ribavirin. (3) To test the influence of
      combination therapy on HOMA IR
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total 300 treatment-naïve chronic hepatitis C patients will be enrolled. The prevalence of
      NIDDM, IGT and IR will be explored in this hospital-based study among the clinically defined
      chronic hepatitis C Taiwanese. The clinical manifestations of chronic hepatitis C in the
      biochemical, virological and histopathological aspects will be evaluated. Liver enzymes will
      be measured on a multichannel autoanalyzer. Virological markers for HCV including serum HCV
      RNA detected using a standardized automated qualitative PCR assay, HCV RNA genotypes
      determined for genotypes 1a, 1b, 2a, 2b and 3a and serum HCV RNA levels measured by using the
      branched DNA assay. The liver histology will be assessed for scoring the disease activity
      grade quantitatively according to the histological activity index (HAI). Patients are
      assigned a diagnosis of DM if there was documented use of oral hypoglycemic medication or
      insulin, random glucose in excess of 200 mg/dL, or fasting glucose greater than 126 mg/dL on
      two occasions. A standard oral glucose tolerance test (OGTT) will be performed. In addition
      to an OGTT, a history of diabetes mellitus by chart review and/or questionnaire will be also
      obtained. Standard antiviral therapy will be carried out with PEG-IFN, given subcutaneously
      weekly plus 1,000-1,200 mg of oral ribavirin daily. Patients will receive another 24 week of
      follow-up period to determine the virological response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response (SVR) rate, HCV RNA seronegative by PCR throughout 24-week off-treatment period; biochemical, virological and histological characteristics of CHC patients; HOMA-IR change after combination therapy</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon alpha and ribavirin</intervention_name>
    <description>standard pegylated interferon alpha and ribavirin</description>
    <arm_group_label>1</arm_group_label>
    <other_name>PEG-IFN-alpha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic hepatitis C patients with positive anti-HCV for more than 6 months and HCV RNA

          2. No overt hepatic failure or decompensated liver cirrhosis (Child-Pugh class B or C) or
             hepatocellular carcinoma.

        Exclusion Criteria:

          1. Positive for hepatitis B surface antigen (HBsAg)or with concomitant human
             immunodeficiency virus infection

          2. With other types of hepatitis including autoimmune hepatitis, primary biliary
             cirrhosis, sclerosing cholangitis, Wilson's disease, alpha 1-antitrypsin deficiency

          3. Current or past history of alcohol abuse (80 mL ethanol per day)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wan-Long Chuang, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Kaohsiung Medical University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999 Feb;29(2):328-33.</citation>
    <PMID>9918906</PMID>
  </reference>
  <reference>
    <citation>Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004 Mar;126(3):840-8.</citation>
    <PMID>14988838</PMID>
  </reference>
  <reference>
    <citation>Lecube A, Hernández C, Simó R, Esteban JI, Genescà J. Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Am J Gastroenterol. 2007 Oct;102(10):2189-95. Epub 2007 Jul 7.</citation>
    <PMID>17617205</PMID>
  </reference>
  <reference>
    <citation>Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat. 2005 May;12(3):283-91.</citation>
    <PMID>15850469</PMID>
  </reference>
  <reference>
    <citation>Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005 Mar;128(3):636-41.</citation>
    <PMID>15765399</PMID>
  </reference>
  <reference>
    <citation>D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol. 2005 Jul;100(7):1509-15.</citation>
    <PMID>15984973</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <last_update_submitted>August 3, 2009</last_update_submitted>
  <last_update_submitted_qc>August 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Wan-Long Chuang</name_title>
    <organization>Kaohsiung Medical University Chung-Ho Memorial Hospital</organization>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>diabetes</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

